Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation
Hikma Pharmaceuticals Price Target
| Target Price | £19.38 |
| Price | £15.90 |
| Potential |
21.89%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Hikma Pharmaceuticals 2027 .
The average Hikma Pharmaceuticals target price is £19.38.
This is
21.89%
register free of charge
£22.58
41.98%
register free of charge
£15.87
0.21%
register free of charge
|
|
| A rating was issued by 22 analysts: 19 Analysts recommend Hikma Pharmaceuticals to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2027 of
21.89%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion £ | 2.53 | 2.69 |
| 6.12% | 6.36% | |
| EBITDA Margin | 29.26% | 24.90% |
| 28.09% | 14.91% |
15 Analysts have issued a sales forecast Hikma Pharmaceuticals 2026 . The average Hikma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2026. The average Hikma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share £ | 1.64 | 1.78 |
| 35.54% | 8.54% | |
| P/E | 8.94 | |
| EV/Sales | 1.64 |
15 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Mar 04 2026 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Jan 22 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Jan 09 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Jun 22 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Mar 04 2026 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Jan 22 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Jan 09 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
